Nurix Therapeutics NRIX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$2.96M (10 inflow days, 10 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 34.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has held roughly steady near 17.33% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Morgan Stanley | Public Company | 2026/Q3 | +484,027 | 4.8% |
| JPMorgan Chase & Co. | Public Company | 2026/Q3 | +320,853 | 0.3% |
| Russell Investment Management, LLC | Mutual Fund | 2026/Q3 | +318,517 | 0.5% |
| Deutsche Asset & Wealth Management | Mutual Fund | 2026/Q3 | +216,994 | 0.3% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q3 | +207,694 | 0.3% |
| Barclays PLC | Public Company | 2026/Q3 | +161,968 | 0.2% |
| Perceptive Advisors LLC | VC/PE Fund | 2026/Q3 | +1,216,207 | 5.1% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +195,787 | 0.5% |
| Rubric Capital Management LP | Hedge Fund | 2026/Q3 | +4,753,893 | 6.6% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +2,146,354 | 5.0% |
| Vestal Point Capital, LP | Hedge Fund | 2026/Q3 | +1,550,000 | 7.4% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q3 | +1,391,211 | 7.1% |
| Capital Research | Mutual Fund | 2026/Q3 | +894,589 | 1.6% |
| Dimensional Fund Advisors | Mutual Fund | 2026/Q3 | +650,621 | 1.3% |
| Soleus Capital Management, L.P. | Hedge Fund | 2026/Q3 | +527,000 | 1.3% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 3 Nov 2026 | Johannes Van Houte | Chief Financial Officer | Automatic Disposition | -4,769 | $16.20 | 42,745 |
| 2 Nov 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Intent to Sell (Form 144) | -6,113 | $25.70 | – |
| 2 Nov 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Automatic Disposition | -10,929 | $26.76 | 4,406 |
| 1 Nov 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -5,786 | $25.74 | 4,406 |
| 1 Nov 2026 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $26.80 | 123,452 |
| 29 Oct 2026 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Sale | -2,834 | $26.28 | 47,514 |
| 29 Oct 2026 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Retained | +7,348 | – | 47,514 |
| 29 Oct 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -3,957 | $26.28 | 15,335 |
| 29 Oct 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Retained | +6,225 | – | 15,335 |
| 29 Oct 2026 | Gwenn Hansen | Chief Scientific Officer | Open Market Disposition | -3,957 | $26.28 | 123,452 |
| 29 Oct 2026 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Retained | +10,182 | – | 123,452 |
| 14 Oct 2026 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $25.00 | 117,227 |
| 13 Oct 2026 | Julia Gregory | Independent Chairperson | Derivative Exercise and Sale | -22,583 | $23.40 | 10,750 |
| 1 Oct 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -5,786 | $23.19 | 9,110 |
| 1 Sep 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -5,787 | $26.64 | 9,110 |
| 31 Aug 2026 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $25.47 | 117,227 |
| 4 Aug 2026 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -4,356 | $25.00 | 117,227 |
| 3 Aug 2026 | Johannes Van Houte | Chief Financial Officer | Automatic Disposition | -4,761 | $24.65 | 40,166 |
| 3 Aug 2026 | Gwenn Hansen | Chief Scientific Officer | Automatic Disposition | -4,111 | $24.64 | 117,227 |
| 2 Aug 2026 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Automatic Disposition | -10,802 | $23.05 | 9,110 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 18,936,583 | 17.3% | 7.2 |
| 15 Oct 2026 | 20,607,897 | 18.9% | 9.2 |
| 30 Sep 2026 | 17,657,588 | 17.0% | 9.9 |
| 15 Sep 2026 | 17,976,804 | 17.3% | 14.1 |
| 31 Aug 2026 | 17,950,461 | 17.3% | 15.9 |
| 14 Aug 2026 | 17,984,342 | 17.3% | 18.1 |
No comments yet — be the first to weigh in on NRIX.
Sign in to join the discussion.